197
Views
1
CrossRef citations to date
0
Altmetric
Articles

An assessment of current practices in the treatment of hidradenitis suppurativa: the rise of biologic therapy

, &
Pages 1424-1427 | Received 31 Aug 2020, Accepted 12 Sep 2020, Published online: 23 Sep 2020
 

Abstract

Introduction

Treatments for hidradenitis suppurativa (HS) have changed in the last decade. In this context, we studied how management practices have shifted.

Methods

We analyzed the National Ambulatory Medical Care Survey (NAMCS) from 2010 to 2016 to assess current treatment practices for HS.

Results

There were 1.78 (95% confidence interval 1.35, 2.22) million visits. Antibiotics were observed at 55.7% of visits and observations remained stable over time (p = .9, odds ratio 0.99 [0.73, 1.3]). Pain medications were observed at 15.5% of visits and observations remained stable over time (p = .4, odds ratio [0.87 [0.61, 1.2]). Biologic agents were observed at 0.9% of visits and observations remained stable over time (p = .4, odds ratio 0.61 [0.21, 1.7]). Systemic immunomodulators were observed at 2.6% of visits and observations remained stable over time (p = .08, odds ratio 0.42 [0.12, 1.1]). 100% of biologic agents and 88% of systemic immunomodulators were prescribed by dermatologists.

Discussion

The use of biologic agents did not increase in this interval, but it is higher than in an earlier assessment of the NAMCS. Nearly all systemic immunomodulators are prescribed by dermatologists. The ambulatory uptake of these agents did not alter the use of other treatment modalities within this timeframe.

Disclosure statement

Dr. Fleischer is a consultant for Boerhringer-Ingelheim, Dermavant, Incyte, Qurient, SCM Lifescience and Syneos. He is an investigator for Galderma, Menlo and Trevi. He has no other potential conflicts including Honoraria, Speakers bureau, Stock ownership or options, Expert testimony, Grants, Patents filed, received, pending, or in preparation, Royalties, or Donation of medical equipment. Dr. Flood previously received fellowship funding from AbbVie and Janssen paid directly to her institution.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.